Arthritis

Updated 18 December 2015

Arthritis drug could help beat deadly skin cancer

Scientists seeking treatments for a deadly type of skin cancer say an existing arthritis drug slows the growth of melanomas and could be combined with a drug.

0

Scientists seeking treatments for a deadly types of skin cancer say an existing arthritis drug slows the growth of melanomas and could be combined with a drug under development by Plexxikon and Swiss drug maker Roche.

In laboratory studies using mice and human cancer cells the researchers found that leflunomide, a generic drug commonly used to treat rheumatoid arthritis, also inhibits the growth of melanomas.

If further trials prove successful - both for leflunomide alone and in combination with Roche and Plexxikon's promising new melanoma drug PLX4032 - patients could have access to new treatments in three to five years, they said.

Japanese drug maker Daiichi Sankyo bought Plexxikon for $805 million in March.

Exciting discovery

"This is a really exciting discovery - making use of an existing drug specifically to target melanoma," said Grant Wheeler of Britain's University of East Anglia, who worked on the study with scientists from the Children's Hospital Boston.

Melanomas are tumours of the pigment cells in skin. It is the most aggressive form of skin cancer and affects around 160,000 people worldwide each year.

If caught early, surgery can be used to remove the tumour, but if the cancer returns and spreads there are virtually no good alternative treatments, and conventional chemotherapy typically works in only around 10 to 20% of these cases.

Series of experiments

The British and US scientists began their series of experiments by looking at the effects of various chemical compounds on pigments in frogs and zebra fish. This screening process led them to leflunomide, which they then tested on tumours in mice engrafted with human melanoma cells.

Leflunomide was sold under the brand name Arava by Sanofi-Aventis and is now sold generically by drug makers such as Teva Pharmaceutical Industries.

After seeing that the drug slowed the growth of these tumours, the group combined it with Roche and Plexxikon's drug - a so-called BRAF inhibitor, currently in late stage trials.

"We thought combining that drug, which targets a specific oncogenic mutation, with leflunomide, which changes the cell's lineage, could have a beneficial effect," said Leonard Zon, one of the research team leaders from Children's Hospital Boston.

The results

Their results showed that it did. Compared with each drug alone, the combination led to a marked decrease in melanoma, the researchers said, and even with low doses of each drug the tumours disappeared completely in 40% of the mice.

The researchers said the results from these studies, which were published online in the journal Nature, mean human trials could start within the next 6 months, since the safety of both drugs has already been established.

"Deaths from melanoma skin cancer are increasing and there's a desperate need for new, more effective treatments," Wheeler said. "If this does what we think it will, and we find patients are responding to it in the trials, it could be used in patients in three to five years."

Bristol-Myers Squibb also has a new experimental melanoma drug called ipilimumab in late stage trials. Preliminary data released this week showed it extended survival of previously untreated patients with advanced forms of the disease.

Read more:  

Cancer centre

Preventing skin cancer

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Arthritis expert

Professor Asgar Ali Kalla completed his MBChB (Bachelor of Medicine and Bachelor of Surgery) degree in 1975 at the University of Cape Town and his FRCP in 2003 in London. Professor Ali Kalla is the Isaac Albow Chair of Rheumatology at the University of Cape Town and also the Head of Division of Rheumatology at Groote Schuur Hospital. He has participated in a number of clinical trials for rheumatology and is active in community outreach. Prof Ali Kalla is an expert in Arthritis for Health24.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules